TITLE

Buprenorphine alone or in combination with naloxone reduced the use of and craving for opiates in opiate addiction

PUB. DATE
May 2004
SOURCE
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p65
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article presents a study to find out whether buprenorphine alone or in combination with naloxone, is more effective than placebo for reducing the use of opiates and the craving for opiates in opiate-addicted outpatients. 326 patients defined as opiate dependent who were 18 to 59 years of age and were seeking opiate-substitution pharmacotherapy, were taken for the study. 110 patients were allocated to daily, office-based combination treatment with 16-mg sublingual buprenorphine plus 4-mg naloxone for 4 weeks; buprenorphine was administered alone on day 1 and day 2 to minimize the risk for naloxone-induced opiate withdrawal. 106 patients were allocated to buprenorphine alone; 8 mg on day 1, and 16 mg thereafter.
ACCESSION #
13221831

 

Related Articles

  • Office based treatment with buprenorphine plus naloxone, or buprenorphine alone reduces opiate use and craving. Fudala, P. J.; Bridge, T. P.; Herbert, S. // Evidence Based Mental Health;May2004, Vol. 7 Issue 2, p54 

    This article presents results of a clinical trial, which determines the effectiveness of buprenorphine with or without naloxone in reducing opiate use and craving in people addicted to opiates. Adults aged from 18-59 years with opiate dependence seeking opiate substitution pharmacotherapy, were...

  • Benefits of Extended Duration Detoxification.  // Clinical Oncology Alert;Jan2009 Clinical Briefs, Vol. 14 Issue 1, p1 

    The article discusses research being done on extended versus short-term buprenorphine-naloxone for treatment of opioid-addicted youth. It references a study by G. E. Woody et al published in the 2008 issue of "JAMA." The study randomized opioid-addicted adults to either short-term buprenorphine...

  • Commentary. Gowing, Linda R.; Lopatko, Olga // Evidence Based Mental Health;May2004, Vol. 7 Issue 2, p54 

    The focus of this paper is the efficacy and safety of the buprenorphine-naloxone tablet in office based treatment settings. The finding that buprenorphine alone, and the combination of buprenorphine and naloxone have greater efficacy than placebo, is not new information. Indeed the inclusion of...

  • Buprenorphine Antinociception is Abolished, but Naloxone-Sensitive Reward is Retained, in μ-Opioid Receptor Knockout Mice. Ide, Soichiro; Minami, Masabumi; Satoh, Masamichi; Uhi, George R.; Sora, Ichiro; Ikeda, Kazutaka // Neuropsychopharmacology;Sep2004, Vol. 29 Issue 9, p1656 

    Buprenorphine is a relatively nonselective opioid receptor partial agonist that is used in the management of both pain and addiction. To improve understanding of the opioid receptor subtypes important for buprenorphine effects, we now report the results of our investigation on the roles of...

  • Buprenorphine Sublingual and Buccal (opioid dependence).  // AHFS Consumer Medication Information;May2017, p1 

    Buprenorphine (Subutex) and buprenorphine and naloxone (Suboxone) are used to treat opioid dependence (addiction to opioid drugs, including heroin and narcotic painkillers). Buprenorphine is in a class of medications called opioid partial agonist-antagonists, and naloxone is in a class of...

  • Buprenorphine in a Transdermal Therapeutic System — A New Option. Bo¨hme, K. // Clinical Rheumatology;Feb2002 Supplement 1, Vol. 21, pS13 

    : Advanced patch technology has yielded a novel transdermal therapeutic system (TDS) for the rate-controlled systemic delivery of buprenorphine. Buprenorphine TDS is available in three strengths with release rates of 35, 52.5 and 70 mg/h over 72 h, corresponding to daily doses of 0.8, 1.2 and...

  • Counseling Buprenorphine Patients: Information and Treatment Approaches for Counselors. McCann, Michael J. // Journal of Psychoactive Drugs;May2004 Supplement 2, Vol. 36, p139 

    The Drug Addiction Treatment Act of 2000 allows qualifying physicians to prescribe buprenorphine out of office-based practices to treat opioid-dependent patients, with the requirement that they have the ability to refer them to ancillary counseling services. It is likely that these patients will...

  • A NEW APPROACH OF CONDUCTING RAPID TRANSFER TO BUPRENORPHINE AMONG ADDICTS WHO DID NOT FUNCTION EVEN ON EXTREMELY HIGH METHADONE DOSES. Sakoman, Slavko // Alcoholism: Journal on Alcoholism & Related Addictions;2008 Supplement 1, Vol. 44, p23 

    Since the initiation of methadone treatment of heroin addicts (1991), the number of heavy and complex cases of drug addicts that could not be stabilized using different approaches, including the usage of high daily doses of methadone, has significantly increased. Even in addicts with whom good...

  • Poor Man's Smack: A qualitative study of buprenorphine injecting in Melbourne, Australia. Horyniak, Danielle; Armstrong, Stuart; Higgs, Peter; Wain, David; Aitken, Campbell // Contemporary Drug Problems;Fall2007, Vol. 34 Issue 3, p525 

    Cross-sectional studies indicate that diversion and injection of buprenorphine intended for oral use is an emerging health issue for Victorian injecting drug users (IDUs). Between June and September 2006 we conducted in-depth interviews with 23 IDUs from Melbourne, Australia, exploring their...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics